Travere Therapeutics, Inc. (TVTX) Gets USPTO Allowance for FILSPARI FSGS Method Patent to 2037
Travere said the USPTO issued a Notice of Allowance for a U.S. patent application covering certain methods of using FILSPARI (sparsentan) in FSGS, with protection expected into Oct 2037. The company plans to list the patent in the FDA Orange Book after issuance.Material DetailsContext by AI Analyst…